After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
Eli Lilly said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.
Lilly will cut about 3,500 positions around the world, resulting in yearly savings of about $500 million, beginning in 2018. The company's shares rose 1.8 percent.
The company expects most of the cuts to come from a voluntary early-retirement program it is offering in the United States. It is also closing a plant in Iowa and research and development offices in New Jersey and China.
Lilly's operating margins have lagged behind those of the company's rivals, according to Morningstar analyst Damien Conover.
"Lilly's R&D as a percentage of sales has trended a bit high over the last couple of years," Conover said. "Part of this is to try to get its operating margins more in alignment with the overall group."
Lilly expects charges of about $1.2 billion before tax, or $0.80 per share after tax.
Lilly outlined in July a likely multi-year delay for its experimental rheumatoid arthritis drug baricitinib, after the U.S. Food and Drug Administration declined to approve the drug, calling for an additional clinical study.
That delay followed the failure of a trial in November of Lilly's experimental Alzheimer's treatment solanezumab, which the company had hoped would be the first medicine approved to slow progression of the disease.
The company said it has the potential to launch two new medicines by the end of 2018 - a breast cancer drug and a treatment for migraines. The FDA is currently reviewing abemaciclib to treat advanced breast cancer.
Lilly shares rose $1.46 to $81.97 in afternoon trading.